

Tetsuzo Tagawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9315184/publications.pdf>

Version: 2024-02-01

100
papers

1,699
citations

304743

22
h-index

361022

35
g-index

101
all docs

101
docs citations

101
times ranked

2872
citing authors

#	ARTICLE	IF	CITATIONS
1	IgG4-Related Lung Disease Exhibiting the Invasion into the Diaphragm: A Case Report. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2022, 28, 223-226.	0.8	2
2	Consideration of the Optimal Surgical Procedure Based on the Risk of Recurrence in Clinical Stage 0 or IA Lung Adenocarcinoma. <i>Anticancer Research</i> , 2022, 42, 1137-1142.	1.1	1
3	The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors. <i>PLoS ONE</i> , 2022, 17, e0263247.	2.5	8
4	A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study. <i>BMC Cancer</i> , 2022, 22, 503.	2.6	10
5	Relationship between consolidation tumor ratio and tumor-infiltrating lymphocytes in small-sized lung adenocarcinoma. <i>Thoracic Cancer</i> , 2022, 13, 2134-2141.	1.9	4
6	Interleukin-38 promotes tumor growth through regulation of CD8+ tumor-infiltrating lymphocytes in lung cancer tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 123-135.	4.2	22
7	First-line osimertinib for leptomeningeal metastasis from lung adenocarcinoma with EGFR mutation as the initial and solitary site of postoperative recurrence. <i>International Cancer Conference Journal</i> , 2021, 10, 78-82.	0.5	0
8	Prognostic Impact of Smoking Period in Patients with Surgically Resected Non-small Cell Lung Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 685-694.	1.5	9
9	Clinical features and prognostic impact of coexisting autoimmune disease other than myasthenia gravis in resected thymomas: analysis of a Japanese multi-institutional retrospective database. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 59, 641-649.	1.4	5
10	Limb arteriolar vasculitis induced by pembrolizumab plus chemotherapy in a patient with lung cancer. <i>International Cancer Conference Journal</i> , 2021, 10, 83-86.	0.5	1
11	Preoperative prognostic nutritional index level is associated with tumour-infiltrating lymphocyte status in patients with surgically resected lung squamous cell carcinoma. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 60, 393-401.	1.4	14
12	Mutational signatures in squamous cell carcinoma of the lung. <i>Journal of Thoracic Disease</i> , 2021, 13, 1075-1082.	1.4	4
13	Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors. <i>Lung Cancer</i> , 2021, 152, 27-33.	2.0	35
14	Prognostic Impact of Albumin-bilirubin (ALBI) Grade on Non-small Lung Cell Carcinoma: A Propensity-score Matched Analysis. <i>Anticancer Research</i> , 2021, 41, 1621-1628.	1.1	14
15	Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting. <i>International Journal of Cancer</i> , 2021, 149, 473-482.	5.1	35
16	Spontaneous hemopneumothorax with a ruptured aneurysm in the second intercostal artery: report of a case. <i>General Thoracic and Cardiovascular Surgery</i> , 2021, 69, 1133-1136.	0.9	1
17	Albumin-bilirubin grade as a significant prognostic factor in patients with non-small cell lung cancer treated with anti-PD-1-based therapy: A multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21125-e21125.	1.6	0
18	Identification of SLC38A7 as a Prognostic Marker and Potential Therapeutic Target of Lung Squamous Cell Carcinoma. <i>Annals of Surgery</i> , 2021, 274, 500-507.	4.2	8

#	ARTICLE	IF	CITATIONS
19	Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib. <i>Lung Cancer</i> , 2021, 158, 156-161.	2.0	4
20	Prognostic value of postoperative decrease in serum albumin on surgically resected early-stage non-small cell lung carcinoma: A multicenter retrospective study. <i>PLoS ONE</i> , 2021, 16, e0256894.	2.5	7
21	Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1745-1753.	4.2	1
22	Radiologic Features of Resected Lung Adenocarcinoma With Epithelial-Mesenchymal Transition. <i>Annals of Thoracic Surgery</i> , 2021, 112, 1647-1655.	1.3	0
23	Combined Evaluation of Tumor-Infiltrating CD8 ⁺ and FoxP3 ⁺ Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 2102-2109.	1.5	16
24	Prognostic Impact of Postoperative Skeletal Muscle Decrease in Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2020, 109, 914-920.	1.3	19
25	Relationship between obstructive lung disease and non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 1145-1146.	1.4	0
26	Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease-free survival in individuals with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 2830-2839.	1.9	4
27	LINE-1 Hypomethylation Is Associated With Malignant Traits and Cell Proliferation in Lung Adenocarcinoma. <i>Anticancer Research</i> , 2020, 40, 5659-5666.	1.1	5
28	Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2639-2650.	2.5	10
29	Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. <i>Lung Cancer</i> , 2020, 145, 18-26.	2.0	57
30	NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration. <i>Lung Cancer</i> , 2020, 146, 97-104.	2.0	21
31	Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1217-1225.	2.5	42
32	Predictive and prognostic impact of primary tumor-bearing lobe in nonsmall cell lung cancer patients treated with anti-PD-1 therapy. <i>International Journal of Cancer</i> , 2020, 147, 2327-2334.	5.1	5
33	Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis. <i>Cancer Science</i> , 2020, 111, 2482-2487.	3.9	14
34	Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study. <i>PLoS ONE</i> , 2020, 15, e0241580.	2.5	8
35	Does short-term cessation of smoking before lung resections reduce the risk of complications?. <i>Journal of Thoracic Disease</i> , 2020, 12, 7127-7134.	1.4	7
36	Pulmonary metastasis presenting as a ground glass opacity-like lesion with a thin-walled cavity: A case report. <i>International Journal of Surgery Case Reports</i> , 2019, 60, 287-290.	0.6	2

#	ARTICLE	IF	CITATIONS
37	The Influence of Clinical T Factor on Predicting Pathologic N Factor in Resected Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2019, 108, 1080-1086.	1.3	6
38	The evolution of surgical treatment for gastrointestinal cancers. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1333-1349.	2.2	7
39	18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer. <i>Scientific Reports</i> , 2019, 9, 13362.	3.3	39
40	A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas. <i>Annals of Thoracic Surgery</i> , 2019, 107, 393-400.	1.3	33
41	Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma. <i>PLoS ONE</i> , 2019, 14, e0217991.	2.5	5
42	Prognosis of Early-stage Part-solid and Pure-solid Lung Adenocarcinomas. <i>Anticancer Research</i> , 2019, 39, 2665-2670.	1.1	9
43	A novel prognostic marker in patients with non-small cell lung cancer: musculo-immuno-nutritional score calculated by controlling nutritional status and creatine kinase. <i>Journal of Thoracic Disease</i> , 2019, 11, 927-935.	1.4	14
44	Clinical and Prognostic Significance of the Epithelialâ€“Mesenchymal Transition in Stage IA Lung Adenocarcinoma: A Propensity Scoreâ€“Matched Analysis. <i>Clinical Lung Cancer</i> , 2019, 20, e504-e513.	2.6	12
45	The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelialâ€“mesenchymal transition in resected lung adenocarcinoma. <i>PLoS ONE</i> , 2019, 14, e0215103.	2.5	11
46	Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients. <i>Annals of Surgical Oncology</i> , 2019, 26, 1916-1924.	1.5	25
47	A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 1925-1933.	1.5	23
48	Localized malignant pleural mesothelioma mimicking an anterior mediastinal tumor. <i>European Journal of Radiology Open</i> , 2019, 6, 72-77.	1.6	11
49	Association of Low Body Mass Index With Poor Clinical Outcomes After Resection of Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 1987-1996.	1.1	11
50	The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation. <i>Annals of Surgical Oncology</i> , 2019, 26, 1544-1551.	1.5	3
51	HMGB1 blockade significantly improves luminal fibrous obliteration in a murine model of bronchiolitis obliterans syndrome. <i>Transplant Immunology</i> , 2019, 53, 13-20.	1.2	1
52	The prognostic impact of obstructive lung disease on survival of never smokers with resected non-small-cell lung cancer: a comparison with smokers. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2019, 28, 735-743.	1.1	5
53	Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy. <i>Lung Cancer</i> , 2019, 128, 26-32.	2.0	24
54	The role of surgical resection for distant metastasis of head and neck squamous cell carcinoma. <i>Japanese Journal of Head and Neck Cancer</i> , 2019, 45, 314-317.	0.1	0

#	ARTICLE	IF	CITATIONS
55	The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study. <i>Annals of Surgical Oncology</i> , 2018, 25, 1555-1563.	1.5	19
56	Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the Lung. <i>Annals of Surgical Oncology</i> , 2018, 25, 1564-1571.	1.5	23
57	Significance of Spread Through Air Spaces in Resected Pathological Stage I Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2018, 105, 1655-1663.	1.3	76
58	Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers. <i>Surgical Oncology</i> , 2018, 27, 88-94.	1.6	41
59	Significance of Spread Through Air Spaces in Resected Lung Adenocarcinomas With Lymph Node Metastasis. <i>Clinical Lung Cancer</i> , 2018, 19, 395-400.e1.	2.6	25
60	Clinical Impact and Risk Factors for Skeletal Muscle Loss After Complete Resection of Early Non-small Cell Lung Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 1229-1236.	1.5	39
61	PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. <i>Lung Cancer</i> , 2018, 116, 1-6.	2.0	51
62	Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph node-positive lung cancer patients. <i>Cancer Science</i> , 2018, 109, 154-165.	3.9	36
63	Atezolizumab in non-squamous non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S3155-S3159.	1.4	4
64	miR-3148 Is a Novel Onco-microRNA that Potentiates Tumor Growth <i>In Vivo</i> . <i>Anticancer Research</i> , 2018, 38, 5693-5701.	1.1	9
65	PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 5897-5901.	1.1	17
66	Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 5903-5907.	1.1	11
67	Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study. <i>In Vivo</i> , 2018, 32, 1541-1550.	1.3	4
68	Radiological Features of IDO1 ⁺ /PDL1 ⁺ Lung Adenocarcinoma: A Retrospective Single-institution Study. <i>Anticancer Research</i> , 2018, 38, 5295-5303.	1.1	6
69	Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5093-5101.	2.0	43
70	The significant influence of having children on the postoperative prognosis of patients with nonsmall cell lung cancer: A propensity score-matched analysis. <i>Cancer Medicine</i> , 2018, 7, 2860-2867.	2.8	4
71	Significance of spread through air spaces in early-stage lung adenocarcinomas undergoing limited resection. <i>Thoracic Cancer</i> , 2018, 9, 1255-1261.	1.9	27
72	Stevens-Johnson Syndrome Induced by Pembrolizumab in a Lung Cancer Patient. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1798-1799.	1.1	27

#	ARTICLE	IF	CITATIONS
73	Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma. <i>European Journal of Cancer</i> , 2018, 101, 20-29.	2.8	35
74	Computed tomography features of resected lung adenocarcinomas with spread through air spaces. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 156, 1670-1676.e4.	0.8	65
75	Recurrent idiopathic pulmonary hemosiderosis after long-term remission presented with Sjogren's syndrome: Idiopathic no more?. <i>Respiratory Medicine Case Reports</i> , 2018, 25, 68-72.	0.4	12
76	A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 124, 255-259.	2.0	14
77	Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors. <i>Surgical Oncology</i> , 2018, 27, 637-641.	1.6	10
78	Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 3707-3711.	1.1	9
79	Radiological Features of Brain Metastases from Non-small Cell Lung Cancer Harboring EGFR Mutation. <i>Anticancer Research</i> , 2018, 38, 3731-3734.	1.1	14
80	Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 553-557.	1.1	19
81	High Frequency of Spread Through Air Spaces in Resected Small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 1821-1825.	1.1	17
82	Which Primary Organ Is Most Suitable for Performing Pulmonary Metastasectomy?. <i>Anticancer Research</i> , 2018, 38, 1041-1045.	1.1	5
83	Safety of Simultaneous Bilateral Pulmonary Resection for Metastatic Lung Tumors. <i>Anticancer Research</i> , 2018, 38, 1715-1719.	1.1	5
84	Successful Treatment of Growing Teratoma Syndrome of the Lung by Surgical Resection: A Case Report and Literature Review. <i>Anticancer Research</i> , 2018, 38, 3115-3118.	1.1	1
85	Takotsubo Cardiomyopathy Developed After Two-stage Surgery for Double Primary Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 2957-2960.	1.1	2
86	Underlying Problems in Surgical Treatment of cT1-2N1 Non-Small Cell Lung Cancer. <i>Thoracic and Cardiovascular Surgeon</i> , 2017, 65, 130-135.	1.0	0
87	Surgical Outcomes of Non-small Cell Lung Cancer in Patients with a History of Pancreaticobiliary Cancer. <i>Anticancer Research</i> , 2017, 37, 3307-3309.	1.1	5
88	Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab. , 2017, 37, 5713-5717.		24
89	Association Between PD-L1 Expression and Metabolic Activity on 18F-FDG PET/CT in Patients with Small-sized Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 7073-7082.	1.1	32
90	Surgical Resection and Outcome of Synchronous and Metachronous Primary Lung Cancer in Breast Cancer Patients. , 2017, 37, 5871-5876.		3

#	ARTICLE	IF	CITATIONS
91	Prognostic Significance of Expression of the Epithelial-Mesenchymal Transition-Related Factor Brachyury in Intrathoracic Lymphatic Spread of Non-Small Cell Lung Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 1012-1020.	1.5	9
92	Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 101, 92-97.	2.0	105
93	A case of surgical treatment for systemic origin of an aberrant artery to the basal segments of the left lung. <i>The Journal of the Japanese Association for Chest Surgery</i> , 2016, 30, 236-242.	0.0	0
94	PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 62-71.	1.1	144
95	Prognostic Impact of EGFR Driver Mutations on Postoperative Disease Recurrence in Lung Adenocarcinoma. <i>Anticancer Research</i> , 2016, 36, 3057-63.	1.1	11
96	Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. <i>Journal of Thoracic Disease</i> , 2015, 7, 1898-906.	1.4	17
97	Associations between driver gene mutations and cytotoxic chemosensitivity in patients with non-small cell lung cancer. <i>Anticancer Research</i> , 2015, 35, 1791-6.	1.1	3
98	Liver transplantation followed by pulmonary resection complicated with end-stage liver cirrhosis: a case report. <i>Anticancer Research</i> , 2015, 35, 3411-4.	1.1	1
99	Intrapleural Hypotonic Cisplatin Treatment for Malignant Pleural Mesothelioma: In Vitro Experiments and Clinical Application. <i>Surgery Today</i> , 2006, 36, 135-139.	1.5	4
100	VÎ1+ Î³Î T Cells Producing CC Chemokines May Bridge a Gap between Neutrophils and Macrophages in Innate Immunity during <i>Escherichia coli</i> Infection in Mice. <i>Journal of Immunology</i> , 2004, 173, 5156-5164.	0.8	37